Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Evome Medical Technologies Inc V.EVMT

Alternate Symbol(s):  LNDZF

Evome Medical Technologies Inc. is an international medical device company, which is focused on human performance and rehabilitative solutions. The Company’s products include Biodex Rehab product, Damar Plastics product, Mio-Guard product, Simbex services, and SDP product. Its Biodex Rehab products include Isokinetic Systems, Gait Trainer, Body-Weight Supported Training, Cycles and Ergometers, and Squat-Assist Trainer. Its Mio-Guard products include bags, cases and kits, braces, and supports, diagnostics and instruments, furniture, and equipment, padding and splinting, personal protection, sanitizers and disinfectants, and tapes and wraps. Its applications include fall risk screening and conditioning, patient-driven payment model (PDPM), wellness, sports medicine solutions, neurological involvement, safe patient handling and mobility, and senior living and rehabilitation. It offers concussion, fall screening and balance assessment and training programs.


TSXV:EVMT - Post by User

Comment by zxcvbnnmon Mar 08, 2018 3:42pm
65 Views
Post# 27686160

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:This link might explain why you are nervous Newcoin...

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:This link might explain why you are nervous Newcoin...You should not deviate from relavant discussions. Your argumens tend to be extreme, and lack an objective perspective.

Despite what have happened in the past which is the reason why the stock is trading at a huge discount to the net cash value, what will likely happen next is most relavent at this point. 

Given that the company is working on a transaction to sell the loan division or monetize it, upon announcement or completion, the share price should respond corresponsively at least increase close to the net book value should the company distribute the proceeds to shareholders or the company receive shares from the acquired company. This is assuming there is no premium to be sold/montetized for the loan division. Any premium of course will result in further upside potential.

On the other hand, the billing division continues to show signs of growth and potentially will bring more revenue as it currently stands close to $2.5M per year. If acheived, again will provide further upside potential.

So overall, we start with 37.4 cents net cash position, not even including any upside potential, and now it is trading between 17-18 cents.

Buy or sell, you decide.  
Bullboard Posts